Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Alto Neuroscience Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 2 distinct art units, indicating examiner coverage that extends across more than one USPTO examination group.
BAEK, BONG-SOOK is the busiest examiner, with 1 pending matter. Because that figure is not greater than the pending workload assigned to other examiners, prosecution attention is distributed rather than concentrated with one examiner. Counsel should track responses across both art units and maintain a consistent biotechnology prosecution position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19040204 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | BAEK, BONG-SOOK | — |
| 18896294 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | BORI, IBRAHIM D | — |
| 18892030 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | WEDDINGTON, KEVIN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19040204 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | BAEK, BONG-SOOK | — |
| 18896294 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | BORI, IBRAHIM D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19040204 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | BAEK, BONG-SOOK | 1611 | §101§103§112DP | Final Rejection | — | Pending | Jan 29, 2025 |
| 18896294 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | BORI, IBRAHIM D | — | §102§103 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18892030 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | WEDDINGTON, KEVIN E | 1629 | §103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlto Neuroscience Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Bong-Sook Baek has the most, with 1 of Alto Neuroscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.